Celldex - Why it's moving again and what's in store?

After being "let go" by Pfizer last year, the stock has seen several lows and then seems to be picking itself up again. This article seeks to discuss the potential for Celldex with its current trials/pipeline etc. Any input from other knowledgeable folks/traders etc appreciated.

Rindopepimut (CDX-110): Clinical Program (source:http://www.celldextherapeutics.com/wt/page/cdx_110)

Rindopepimut (CDX-110) is an immunotherapy that targets the tumor specific molecule called EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy.

A list of upcoming events are normally shown here.

I am going to be adding more here in collaboration with inputs from Yahoo message board members and other pharma friends of mine.